Premalignant Conditions of the Esophagus

Czech version

Authors: R. Kroupa
Authors‘ workplace: Interní gastroenterologická klinika LF MU a FN Brno
Published in: Klin Onkol 2013; 26(Supplementum): 17-21

Overview

Esophageal cancer has often poor survival when it is diagnosed at the time of clinical symptoms. Precancerous lesions of the esophagus are targets of interest in selected group of patients with important risk factors. Barrett’s esophagus – intestinal metaplasia is the main precursor lesion for the development of esophageal adenocarcinoma, the tumor with increased incidence. The major risk factor for Barrett’s esophagus is long‑term gastroesophageal reflux disease. In addition to antireflux therapy, the endoscopic surveillance and follow‑up are scheduled in order to detect adenocarcinoma and its precursor dysplastic lesions at an early and curable stage. The patients with achalasia, caustic injury of the esophagus and those with head and neck cancer are at increased risk of development of the squamous cell esophageal cancer. The aim of this paper is to provide an overview of the risk factors, epidemiology, screening and surveillance of premalignant lesions of the esophagus. Recent endoscopic and surgical procedures to treat advanced dysplastic lesions and early cancer are discussed.

Key words:
adenocarcinoma – squamous cell carcinoma – Barrett’s esophagus – precancerous conditions – early detection of cancer – endoscopy – digestive system

This study was supported by grant of the Czech Ministry of Health – RVO (FNBr, 65269705).

The author declare he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
12. 9. 2013

Accepted:
27. 9. 2013

Sources

1. Magnusková S, Kollárova H, Kamarád V et al. Dvojí tvář rakoviny jícnu – epidemiologie a etiologie. Gastroent Hepatol 2011; 65(5): 255– 263.

2. Kubo A, Block G, Quesenberry CP Jr. Effects of dietary fiber, fats, and meat intakes on the risk of Barrett‘s esophagus. Nutr Cancer 2009; 61(5): 607– 616.

3. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, [cit. 2013– 8– 24]. Dostupný z: www.svod.cz.

4. Hirota WK, Zuckerman MJ, Adler DG et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63(4): 570– 580.

5. Cooper JS, Pajak T, Rubin P et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17(3): 449– 456.

6. Vítek P, Komínek P, Kajzrlíková I et al. Endoskopická diagnostika a léčba časného spinocelulárního karcinomu jícnu je možná i v populaci s nízkou incidencí tohoto onemocnění. Endoskopie 2009; 18(4): 161– 166.

7. Moschler O, Spahn TW, Middelberg‑ Bisping C et al. Chromoendoscopy is a valuable tool for screening of high‑risk patients with head and neck cancer for early detection of esophageal cancer. Digestion 2006; 73(2– 3): 160– 166.

8. Su YY, Chen WC, Chuang HC et al. Effect of routine esophageal screening in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 2013; 139(4): 350– 354.

9. Petit T, Georges C, Jung GM et al. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous‑ cell carcinoma. Ann Oncol 2001; 12(5): 643– 646.

10. Bergman JJ, Zhang YM, He S et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointestinal Endoscopy 2011; 74(6): 1181– 1190.

11. Vakil N, van Zanten SV, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‑based consensus. Am J Gastroenerol 2006; 101(8): 1900– 1920.

12. Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett‘s esophagus. Gastroenterology 2011; 140(3): e18– e52.

13. Sharma P. Clinical practice. Barrett‘s esophagus. N Engl J Med 2009; 361(26): 2548– 2556.

14. Dent J. Barrett‘s esophagus: A historical perspective, an update on core practicalities and predictions on future evolutions of management. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 11– 30.

15. Malfertheiner P, Nocon M, Vieth M et al. Evolution of gastro‑esophageal reflux disease over 5 years under routine medical care – the ProGERD study. Aliment Pharmacol Ther 2012; 35(1): 154– 164.

16. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4(5): 566– 572.

17. Hvid‑ Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett‘s esophagus. N Engl J Med 2011; 365(15): 1375– 1383.

18. Ayers K, Shi C, Washington K. Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett‘s esophagus. Surg Endosc 2013; 27(8): 2836– 2840.

19. Martínek J, Zavoral M. Barrettův jícen – jak sledovat a jak léčit. Postgraduální medicína 2009; 11(6): 674– 682.

20. Gregar J, Procházka V, Lužná P et al. Využití NBI v diagnostice a sledování pacientů s Barrettovým jícnem. Gastroent Hepatol 2012; 66(3): 165– 169.

21. Voltaggio L, Montgomery EA, Lam‑ Himlin D. A clinical and histopathologic focus on Barrett esophagus and Barrett‑related dysplasia. Arch Pathol Lab Med 2011; 135(10): 1249– 1260.

22. Lukáš K, Bureš J, Drahoňovský V et al. Refluxní choroba jícnu. Standardy České gastroenterologické společnosti – aktualizace 2009. Vnitř Lék 2009; 55(10): 967– 975.

23. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310(6): 627– 636.

24. Bennett C, Vakil N, Bergman J. Consensus statements for management of Barrett‘s dysplasia and early‑stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143(2): 336– 346.

25. Rejchrt S, Repák R, Bureš J. Endoskopická diagnostika a léčba časného adenokarcinomu jícnu. Endoskopie 2009; 18(4): 144– 149.

26. Martínek J, Falt P, Gregar J et al. Radiofrekvenční ablace v gastrointestinálním traktu – aktuální stav ve světě a v ČR. Gastroent Hepatol 2011; 65(5): 279– 285.

27. Phoa KN, Pouw RE, van Vilsteren FG et al. Remission of Barrett‘s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145(1): 96– 104.

28. Corley DA, Kerlikowske K, Verma R et al. Protective association of aspirin/ NSAIDs and esophageal cancer: a systematic review and meta‑analysis. Gastroenterology 2003; 124(1): 47– 56.